An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Abstract
The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. Here, we tested a panel of anti-receptor binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 [Sotrovimab]), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use may lose efficacy against the B.1.1.529 Omicron variant.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 27, 2021
- Source ID
- 10.21203/rs.3.rs-1175516/v1
Entities
People
- Daved H. Fremont
- Davide Corti
- James E. Crowe, Jr.
- John M Errico
- Laura A. VanBlargan
- Lisa Purcell
- Michael S. Diamond
- Peter J Halfmann
- Seth J Zost
- Yoshihiro Kawaoka
Organizations
- University of Wisconsin–Madison
- VIR Biotechnology
- Vanderbilt University
- Washington University School of Medicine
- Washington University in St. Louis